Vildagliptin, a dipeptidyl peptidase-IV inhibitor improves model-assessed beta-cell function in patients with type 2 diabetes

Research output: Contribution to journalJournal article

Original languageEnglish
JournalJ. Clin. Endocrinol. Metab.
Issue number90
Pages (from-to)4888-4894
Publication statusPublished - 2005

ID: 69022